US Markets

Moderna files for U.S. authorization to use its COVID-19 vaccine in teens

Credit: REUTERS/MIKE SEGAR

Moderna Inc said on Thursday it has filed for U.S. authorization to use its COVID-19 vaccine in adolescents aged 12 to 18, the latest company to seek approval to help expand the inoculation drive in the country.

Adds details on the application, background

June 10 (Reuters) - Moderna Inc MRNA.O said on Thursday it has filed for U.S. authorization to use its COVID-19 vaccine in adolescents aged 12 to 18, the latest company to seek approval to help expand the inoculation drive in the country.

Moderna's vaccine is already being used in the United States, the European Union and Canada for anyone over 18. The drugmaker has already submitted applications to the European and Canadian health regulators seeking authorization for the vaccine's use in adolescents.

Moderna's two-shot vaccine last month was shown to be effective in adolescents aged 12-17 and showed no new or major safety problems in a clinical trial which evaluated the vaccine in 3,732 teenagers.

Vaccinating children has been considered key to achieving "herd immunity" and the U.S. has already authorized Pfizer PFE.N and German partner BioNTech SE's 22UAy.DE COVID-19 vaccine for use in children as young as 12.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Bernard Orr)

((manojna.kalyani@thomsonreuters.com; +91 8061822700;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRNA PFE

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More